LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG
Childhood cancer survivors represent a high-risk population that requires risk-based follow-up. Follow-up recommendations have been harmonized. Education and information practices regarding follow-up recommendations should be personalized, to ensure understanding by all survivors, including those with neurocognitive di
| Condition(s) | Pediatric Cancer, Cancer Survivor, Hemato-oncologic Patients |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Childhood cancer survivors represent a high-risk population that requires risk-based follow-up. Follow-up recommendations have been harmonized. Education and information practices regarding follow-up recommendations should be personalized, to ensure understanding by all survivors, including those with neurocognitive disorders. Individualized follow-up is necessary to detect complications that may increase morbidity and decrease quality of life, or even increase the risk of early mortality. In France, the LOG-AFTER software was developed in 2017 by university hospital of Angers and Epiconcept (approved health data host). The main differences with the European procedure concern radiotherapy information, the link with the General practitioner (GP), and the possible addition of information and |
| Who can participate | Inclusion Criteria: * Previously treated for cancer or malignant hematological pathology before the age of 25 * Without residual disease or with a stable disease without treatment for 5 years or more * Owning a computer, smartphone or equivalent I-Pad/tablet with internet access * Having signed the consent (or their parents if the patient is a minor, or a third party if necessary) * Having 3 or more recommended screenings in their survivorship care plan * No access created to LOG-AFTER before the study or having never connected after opening their account if opening an account dating back 24 months or more at the time of inclusion Exclusion Criteria: * Patient who has relapsed or developed a second cancer with a post-treatment delay \< 5 years * Patient not covered by a health insurance * |
| Ages | 15 Years |
| Sex | All |
| Lead sponsor | University Hospital, Angers |
| Locations | Angers, Maine Et Loire, France |
| Start date | 2025-06-06 |
| NCT ID | NCT06939322 |
| Official listing | https://clinicaltrials.gov/study/NCT06939322 |